CANCER CELL BIOLOGY AND SIGNALING PROGRAM (CCBS) ABSTRACT: The purpose of CCBS, a Discipline-Based Program, is to make fundamental mechanistic discoveries into signaling pathways that are dysregulated in human cancer and to translate findings into new treatment opportunities. Common themes are to: 1) Integrate genomic, biochemical and functional analyses to determine the role and dysregulation of signaling pathways in relevant cancer models; 2) Identify mechanisms of resistance to targeted inhibitors; and 3) Characterize the role of the stroma in the tumor microenvironment. Current specific aims are:
Aim 1 : Discover mechanisms regulating cell growth & metastasis by heterotrimeric and monomeric GTPases Aim 2: Characterize the role of the tumor microenvironment in regulating protein kinase signaling pathways and metabolism Aim 3: Identify the regulation and role of inflammation and cytokine signaling The CCBS Program has 42 members that include basic scientists, clinical researchers, and population scientists that have made high-impact discoveries at the bench and in the clinic. Members generated 776 publications, an increase of +19.4% over the prior project period. Of these, 135(17.4%) were intra- programmatic, an increase of +58.2%; 164 were inter-programmatic (21.1%). Overall impact has improved with 7.5% appearing in journals with an impact factor >10 and an average impact factor of 5.6. In 2016, SKCC also began to track collaborations with authors from other NCI-designated Cancer Centers; at present, 34.2% of CCBS Program publications were in collaboration with authors from other NCI-designated Centers. The overall impact of CCBS is illustrated by the number of high-impact fundamental discoveries that have been published in the last funding cycle, including in Cell, PNAS, JAMA, J. Clin Invest., J. Clin Oncol., Nature and Nature Comm. In the last funding period, CCBS members were productive in securing funding. Notably, the mechanism for calculating total and direct costs has changed since the last CCSG review, now requiring exclusion of funding sources that were allowable in the last review. Furthermore, SKCC was last reviewed during the peak of ARRA funding. Despite these barriers in comparing current funding totals versus the last review, CCBS remains strong. Total cancer relevant funding increased from $13.7M to $17.1M total costs (+29.0 %) with direct costs also increasing from $9.4M to $12.2 (+29.8%). Annual peer-reviewed funding is steady from the last review at $11.7M total/ $7.7M direct, with 27.2 % of peer-reviewed funding derived from NCI, and 32.8% from combined federal cancer-dedicated peer review sources (NCI + Department of Defense Cancer Programs).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA056036-21
Application #
9956995
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Sullivan-Reed, Katherine; Bolton-Gillespie, Elisabeth; Dasgupta, Yashodhara et al. (2018) Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep 23:3127-3136
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35
Lapadula, Dominic; Farias, Eduardo; Randolph, Clinita E et al. (2018) Effects of Oncogenic G?q and G?11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res :
Vite, Alexia; Zhang, Caimei; Yi, Roslyn et al. (2018) ?-Catenin-dependent cytoskeletal tension controls Yap activity in the heart. Development 145:
McNair, Christopher; Xu, Kexin; Mandigo, Amy C et al. (2018) Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest 128:341-358
Garcia, Samantha A; Lebrun, Aurore; Kean, Rhonda B et al. (2018) Clearance of attenuated rabies virus from brain tissues is required for long-term protection against CNS challenge with a pathogenic variant. J Neurovirol 24:606-615
Vido, Michael J; Le, Kaitlyn; Hartsough, Edward J et al. (2018) BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Rep 25:1501-1510.e3
Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469
Liao, Lili; Liu, Zongzhi Z; Langbein, Lauren et al. (2018) Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. Elife 7:
Heeke, Arielle L; Pishvaian, Michael J; Lynce, Filipa et al. (2018) Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol 2018:

Showing the most recent 10 out of 807 publications